<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01677338</url>
  </required_header>
  <id_info>
    <org_study_id>URA-12-001</org_study_id>
    <nct_id>NCT01677338</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects</brief_title>
  <official_title>A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, open-label comparison study and aimed to evaluate the&#xD;
      preliminary performance of this 13C-uracil GEBT to examine its abilities of identifying&#xD;
      abnormal (delayed) gastric emptying rates in subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately equal numbers of subjects will be enrolled in each of the 2 groups (with normal&#xD;
      gastric emptying, and with delayed gastric emptying (gastroparesis)) to complete at least 10&#xD;
      subjects per group.&#xD;
&#xD;
      The subjects will first have their gastric emptying rates investigated by scintigraphy using&#xD;
      the Solid Test Meal containing 500 uCi 99mTc sulfur colloid at Visit 1. Second, the subjects&#xD;
      will have their gastric emptying rates investigated by scintigraphy and 13C-uracil GEBT&#xD;
      simultaneously using the Semi solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100&#xD;
      mg of 13C-uracil, respectively, at Visit 2. A comparison will be made between the results&#xD;
      obtained at Visits 1 and 2 along with a comparison of the data obtained during Visit 2 for&#xD;
      evaluation of the 13C-uracil GEBT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expired 13CO2 concentrations</measure>
    <time_frame>6 hours</time_frame>
    <description>Expired 13CO2 concentrations are obtained from breath test. The values will be calculated to Re(t)[B] semi-solid: remaining (%) of semi-solid test meal in stomach at t, t1/2[B] semi solid: half emptying time of semi-solid test meal , and tlag[B] semi-solid: lag time of semi-solid test meal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of 13C-uracil and its major metabolites in plasma and urine</measure>
    <time_frame>6 hours</time_frame>
    <description>PK parameters of 13C-uracil and its major metabolites, DHU and UPA, including AUCt, AUC∞, Cmax, tmax, λz, and t1/2,z, will be calculated based on plasma and urine concentration for 13C-uracil and its metabolites, and expired 13CO2-excretion, which calculated based on expired 13CO2 concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dyspeptic Subjects</condition>
  <arm_group>
    <arm_group_label>13C-uracil and 99mTc sulfur colloid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>99mTc sulfur colloid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C-uracil</intervention_name>
    <description>PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.</description>
    <arm_group_label>13C-uracil and 99mTc sulfur colloid</arm_group_label>
    <other_name>C13-URA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc sulfur colloid</intervention_name>
    <description>PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.</description>
    <arm_group_label>13C-uracil and 99mTc sulfur colloid</arm_group_label>
    <arm_group_label>99mTc sulfur colloid</arm_group_label>
    <other_name>Technetium Tc 99m Sulfur Colloid Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index [range is 18.0 to 33.0 kg/m2&#xD;
&#xD;
          -  Subjects with any upper GI symptoms&#xD;
&#xD;
          -  Stable creatinine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of known peptic ulcers or stomach cancer.&#xD;
&#xD;
          -  History of stomach surgery or resection&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food or other substance, unless approved by the investigator&#xD;
&#xD;
          -  History of alcoholism or drug abuse&#xD;
&#xD;
          -  History or presence of clinically significant GI, cardiovascular, central nervous&#xD;
             system, hepatic, or renal disease; or other conditions&#xD;
&#xD;
          -  History of eating disorders&#xD;
&#xD;
          -  History or presence of an abnormal ECG, which, in the opinion of the investigator, is&#xD;
             clinically significant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimiyoshi Sudoh</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2012</study_first_posted>
  <disposition_first_submitted>October 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2015</disposition_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

